Evaluating the Integraty of Biotechnology Research Tools: Merck v. Integra and the Scope of 35 U.S.C. Section 271(e)(1)

31 Pages Posted: 8 Jan 2009

Date Written: December 1, 2006

Abstract

Congress enacted 35 U.S.C. section 271(e)(1) to provide an exemption for uses of patented products directed toward submitting information to the FDA. Research tool use is "reasonably related" to this information submission, as required by section 271(e)(1). But, the "patented inventions" referred to in section 271(e)(1) refer to inventions that are themselves subject to FDA regulation. Because research tools are not incorporated into the final product submitted to FDA, they are not subject to FDA regulation and therefore are not "patented inventions" under section 271(e)(1). Consequently, research tools do not qualify for the section 271(e)(1) exemption.

Keywords: Patent, Infringement, Hatch-Waxman Safe Harbor

Suggested Citation

Mischnick, Michael R., Evaluating the Integraty of Biotechnology Research Tools: Merck v. Integra and the Scope of 35 U.S.C. Section 271(e)(1) (December 1, 2006). Minnesota Law Review, Vol. 91, No. 2, 2006, Available at SSRN: https://ssrn.com/abstract=1323845

Michael R. Mischnick (Contact Author)

affiliation not provided to SSRN ( email )

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
74
Abstract Views
601
Rank
576,227
PlumX Metrics